ABOUT THIS PROGRAM AND FACULTY DISCLOSURES
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period February 20, 2020 through February 20, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 82 segments, totaling 4.0 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.
Estimated Time to Complete Educational Activity
4.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.
In this web-based program, physicians will learn how recent developments in basic and clinical research have helped to advance the ability to optimize early recognition and confirm the diagnosis of Fabry Disease (FD).
February 20, 2020
February 20, 2022
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients who may have Fabry Disease, including cardiologists, neurologists, nephrologists, clinical genetics specialists, dermatologists, ophthalmologists, internal medicine/primary care specialists, and related clinicians.
Participation in this iQ&A interactive Medical Intelligence Zone is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
This activity is supported by an independent medical education grant from Amicus Therapeutics
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School, Office of CME, and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School, Office of CME designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School, Office of CME to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School, Office of CME are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Robert J. Hopkin, MD
Associate Professor of Clinical Pediatrics
Cincinnati Children's Hospital Medical Center
Co-Director, 22Q-VCFS Center
University of Cincinnati College of Medicine
Consulting: Sanofi Genzyme, Alexion Corp., Amicus Therapeutics, Takeda, Sangamo
Advisory: Sanofi Genzyme, Alexion Corp., Amicus Therapeutics
Speakers’ Bureau: Sanofi Genzyme, Alexion Corp.
Research Grants/Contracts: Sanofi Genzyme, Alexion Corp., Amicus Therapeutics, Takeda, Protalix, Idorsla
John Jefferies, MD
Jay M. Sullivan Endowed Chair in Cardiovascular Medicine
Chief of Cardiology
University of Tennessee Health Science Center (UTHSC).
Co-Director, UT Methodist Institute for Cardiovascular Science
University of Tennessee Heart Institute
Consultant: Sanofi Genzyme, Abbott
Speaker: Sanofi Genzyme, Pfizer
Heather A. Lau, MD
Assistant Professor, Department of Neurology
Associate Director, Division of Neurogenetics
Director, Lysosomal Storage Disease Program
New York, NY
Advisory Board: Amicus Therapeutics, Adult Polyglucosan Body Research Foundation, Avrobio, Biomarin, Chiesi, National Tay-Sachs & Allied Diseases Association, Sanofi Genzyme, Shir
Consulting: from: Amicus Therapeutics, ASPA Therapeutics, BioMarin, Chiesi, Pfizer, Prevail Therapeutics, Sanofi Genzyme, Shire, Ultragenyx Pharmaceutical, Inc.
Contracted research: Amicus Therapeutics, BioMarin, Mallinckrodt, Pfizer, Protalix, Sangamo, Sanofi Genzyme, Shire, Ultragenyx Pharmaceuticals, Inc.
Paula Luna, MD
Director of the Fellowship on Psoriasis
and Other Inflammatory Disease
Buenos Aires, Argentina
Speaker Honoraria: Genzyme, Amicus Therapeutics
Alberto Ortiz, MD
Chief of Nephrology and Hypertension
Renal Unit, IIS-Fundacio?n Jime?nez Di?az
Universidad Auto?noma de Madrid, FRIAT
Consultant/Advisor: Sanofi Genzyme
Speakers Bureau: Amicus Therapeutics, Inc., Sanofi Genzyme, Shire
Grant/Research Support: Sanofi Genzyme
Claire Zar-Kessler, MD
Medical Director, Pediatric Neurogastroenterology Program
Instructor, Harvard Medical School
Mass General Hospital for Children
Honoraria and Contracted Research: Sanofi GenzymeProgram Managers and Web Editor Disclosure
Program Manager Gideon Bosker, MD and Denise Leary have nothing to disclose.
Upon completion of this activity, participants will be able to:
- Recognize the prevalence, unmet clinical needs and under-appreciated clinical burden and “failure to diagnose” syndrome associated with FD in the general population
- Understand the etiology, pathophysiology, inflammatory basis, blood and genetic testing, and multi-system organ evaluation required to facilitate early diagnosis and confirmation of FD
- Discuss the etiology and pathophysiology of FD, including genetic considerations and their potential impact on disease phenotype, and variable time and severity of presentations in male and female patients
- Discuss and compare the diverse mechanisms of action of approved FDA-specific treatments, including agalsidase beta and migalastat.
- Assess the latest clinical evidence supporting the efficacy and safety of FDA-approved therapy, including agalsidase beta and migalastat
- Determine appropriate, patient- and genetic mutation-specific treatment approaches for FD;
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
Copyright © 2020 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC